Efficacy of FOLFOX Chemotherapy in Metastatic Enteropancreatic Neuroendocrine Tumors

被引：8

作者：

Oziel-Taieb, Sandrine ^{[1
]}

Zemmour, Christophe ^{[2
]}

Raoul, Jean-Luc ^{[3
]}

Mineur, Laurent ^{[4
]}

Poizat, Flora ^{[5
]}

Charrier, Nathalie ^{[6
]}

Piana, Gilles ^{[7
]}

Cavaglione, Gerard ^{[8
]}

Niccoli, Patricia ^{[1
]}

机构：

[1] Inst Paoli Calmettes, IPC NET Ctr, ENETS Ctr Excellence, Dept Med Oncol, Marseille, France

[2] Aix Marseille Univ, Inst Paoli Calmettes, Dept Clin Res & Invest, Biostat & Methodol Unit,INSERM,IRD,SESSTIM, Marseille, France

[3] Inst Cancerol Ouest, Dept Digest Oncol, Nantes, France

[4] St Catherine Inst, Gastro Intestinal & Liver Canc Unit, Avignon, France

[5] Inst Paoli Calmettes, IPC NET Ctr, ENETS Ctr Excellence, Dept Biopathol, Marseille, France

[6] Inst Paoli Calmettes, IPC NET Ctr, ENETS Ctr Excellence, Dept Nucl Med, Marseille, France

[7] Inst Paoli Calmettes, IPC NET Ctr, ENETS Ctr Excellence, Dept Radiol, Marseille, France

[8] Ctr Antoine Lacassagne, Dept Med Oncol, Nice, France

来源：

ANTICANCER RESEARCH | 2021年 / 41卷 / 04期

关键词：

Chemotherapy; enteropancreatic neuroendocrine tumors; metastases; oxaliplatin;

D O I：

10.21873/anticanres.14977

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background/Aim: FOLFOX (5-Fluorouracile and oxaliplatin) exhibits promising activity in advanced well-differentiated neuroendocrine tumors (NETs). This retrospective study aimed to analyze the outcome of metastatic enteropancreatic NETS patients treated with FOLFOX. Patients and Methods: We retrospectively identified patients treated with FOLFOX for NETs of enteropancreatic or unknown origin among those referred to our Regional Multidisciplinary Tumor Board. Results: Among 48 patients, most often pancreatic NETs (n=33, 68.8%), the median Ki67 index was 10%. The median number cycle of FOLFOX was 6 and median follow-up was 34.8 months. Disease control rate (DCR) was 83 3%. Median PFS and OS were 12.6 and 29.4 months respectively. Median chemotherapy break was 14.1 months. No significant difference was observed between PFS and the following criteria: Ki67 index, primary tumor site, alkaline phosphatase levels, primary tumor surgery and F-18-FDG PET positivity. Conclusion: FOLFOX exhibits a high DCR and a short duration of treatment with a relative long chemotherapy break in patients with metastatic enteropancreatic NETs.

引用

页码：2071 / 2078

页数：8

共 50 条

[21] Post-first-line FOLFOX chemotherapy for grade 3 neuroendocrine carcinoma [J].

Hadoux, J. ;

Malka, D. ;

Planchard, D. ;

Scoazec, J. Y. ;

Caramella, C. ;

Guigay, J. ;

Boige, V. ;

Leboulleux, S. ;

Burtin, P. ;

Berdelou, A. ;

Loriot, Y. ;

Duvillard, P. ;

Chougnet, C. N. ;

Deandreis, D. ;

Schlumberger, M. ;

Borget, I. ;

Ducreux, M. ;

Baudin, E. .

[22] Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancer [J].

Chua, W. ;

Goldstein, D. ;

Lee, C. K. ;

Dhillon, H. ;

Michael, M. ;

Mitchell, P. ;

Clarke, S. J. ;

Iacopetta, B. .

BRITISH JOURNAL OF CANCER, 2009, 101 (06) :998-1004

[23] Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancer [J].

W Chua ;

D Goldstein ;

C K Lee ;

H Dhillon ;

M Michael ;

P Mitchell ;

S J Clarke ;

B Iacopetta .

British Journal of Cancer, 2009, 101 :998-1004

[24] Modified FOLFOX6 Chemotherapy in Patients with Metastatic Urachal Cancer [J].

Yanagihara, Yutaka ;

Tanji, Nozomu ;

Miura, Noriyoshi ;

Shirato, Akitomi ;

Nishimura, Kenichi ;

Fukumoto, Tetsuya ;

Azuma, Koji ;

Miyauchi, Yuki ;

Kikugawa, Tadahiko ;

Yokoyama, Masayoshi .

CHEMOTHERAPY, 2013, 59 (06) :402-406

[25] Efficacy of Topotecan in Pretreated Metastatic Neuroendocrine Carcinoma [J].

Apostolidis, L. ;

Jaeger, D. ;

Winkler, E. C. .

NEUROENDOCRINOLOGY, 2015, 102 (1-2) :117-118

[26] Oxaliplatin,Fluorouracil and Leucovorin (FOLFOX) as First-line Chemotherapy for Metastatic or Recurrent Colorectal Cancer Patients [J].

Bing Han Ruihua Xu Yanxia Shi Huiyan Luo Xiaojuan Xiang Yuhong Li Li Zhang Tongyu Lin Youjian HeDepartment of Medical OncologySun Yat sen University Cancer CenterGuangzhou China .

Chinese Journal of Clinical Oncology, 2007, (06) :397-400

[27] Neutropaenia as a prognostic factor in metastatic colorectal cancer patients undergoing chemotherapy with first-line FOLFOX [J].

Shitara, Kohei ;

Matsuo, Keitaro ;

Takahari, Daisuke ;

Yokota, Tomoya ;

Inaba, Yoshitaka ;

Yamaura, Hidekazu ;

Sato, Yozo ;

Najima, Mina ;

Ura, Takashi ;

Muro, Kei .

EUROPEAN JOURNAL OF CANCER, 2009, 45 (10) :1757-1763

[28] FOLFOX alternated with FOLFIRI as first-line chemotherapy for metastatic colorectal cancer [J].

Aparicio, Jorge ;

Fernandez-Martos, Carlos ;

Vicent, Jose M. ;

Maestu, Inmaculada ;

Llorca, Cristina ;

Busquier, Isabel ;

Campos, Jan M. ;

Perez-Enguix, Daniel ;

Balcells, Miquel .

CLINICAL COLORECTAL CANCER, 2005, 5 (04) :263-267

[29] Current treatments of neuroendocrine tumors role of biotherapy and chemotherapy [J].

Della Torre, S ;

Procopio, G ;

Fusi, A ;

Catena, L ;

Ferrari, L ;

Nova, P ;

Denaro, A ;

Bichisao, E ;

Bajetta, E .

TUMORI JOURNAL, 2003, 89 (02) :111-116

[30] Control of growth in neuroendocrine gastro-enteropancreatic tumours [J].

Arnold, R ;

Frank, M .

DIGESTION, 1996, 57 :69-71

← 1 2 3 4 5 →